Compass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics (NASDAQ: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapeutics, has announced its participation in two major investor events in May 2025. The company will present at The Citizens Life Sciences Conference in New York on May 8, 2025, at 1:30 PM ET, and at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on May 20, 2025, at 11:30 AM ET. Both presentations will be available via webcast and archived for 90 days on Compass' Events page.
Compass Therapeutics (NASDAQ: CMPX), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie oncologiche basate su anticorpi, ha annunciato la sua partecipazione a due importanti eventi per investitori a maggio 2025. La societ脿 presenter脿 al The Citizens Life Sciences Conference a New York l'8 maggio 2025 alle 13:30 ET, e al H.C. Wainwright 3rd Annual BioConnect Investor Conference presso il NASDAQ il 20 maggio 2025 alle 11:30 ET. Entrambe le presentazioni saranno disponibili in webcast e archiviate per 90 giorni nella pagina Eventi di Compass.
Compass Therapeutics (NASDAQ: CMPX), una empresa biofarmac茅utica en etapa cl铆nica enfocada en desarrollar terapias contra el c谩ncer basadas en anticuerpos, ha anunciado su participaci贸n en dos importantes eventos para inversores en mayo de 2025. La compa帽铆a presentar谩 en The Citizens Life Sciences Conference en Nueva York el 8 de mayo de 2025 a la 1:30 PM ET, y en el H.C. Wainwright 3rd Annual BioConnect Investor Conference en NASDAQ el 20 de mayo de 2025 a las 11:30 AM ET. Ambas presentaciones estar谩n disponibles v铆a webcast y archivadas durante 90 d铆as en la p谩gina de eventos de Compass.
Compass Therapeutics (NASDAQ: CMPX)電� 頃泊 旮半皹 鞎� 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 5鞗旍棎 臧滌禍霅橂姅 霊� 臧滌潣 欤检殧 韴瀽鞛� 頄夓偓鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 2025雲� 5鞗� 8鞚� 鞓ろ泟 1鞁� 30攵�(霃欕秬鞁滉皠)鞐� 雺挫殨鞐愳劀 鞐措Μ電� The Citizens Life Sciences Conference鞐愳劀 氚滍憸頃橂┌, 2025雲� 5鞗� 20鞚� 鞓れ爠 11鞁� 30攵�(霃欕秬鞁滉皠)鞐愲姅 NASDAQ鞐愳劀 鞐措Μ電� H.C. Wainwright 3rd Annual BioConnect Investor Conference鞐愳劀 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 霊� 氚滍憸 氇憪 鞗轨簮鞀ろ姼搿� 鞝滉车霅橂┌, Compass 鞚措菠韸� 韼橃澊歆�鞐愳劀 90鞚缄皠 鞎勳勾鞚措笇搿� 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
Compass Therapeutics (NASDAQ : CMPX), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans le d茅veloppement de traitements anticanc茅reux 脿 base d'anticorps, a annonc茅 sa participation 脿 deux 茅v茅nements majeurs pour investisseurs en mai 2025. L'entreprise pr茅sentera lors de The Citizens Life Sciences Conference 脿 New York le 8 mai 2025 脿 13h30 ET, ainsi qu'au H.C. Wainwright 3rd Annual BioConnect Investor Conference au NASDAQ le 20 mai 2025 脿 11h30 ET. Les deux pr茅sentations seront disponibles en webcast et archiv茅es pendant 90 jours sur la page 脡v茅nements de Compass.
Compass Therapeutics (NASDAQ: CMPX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Antik枚rper-basierten Krebstherapeutika spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenveranstaltungen im Mai 2025 angek眉ndigt. Das Unternehmen wird am The Citizens Life Sciences Conference in New York am 8. Mai 2025 um 13:30 Uhr ET und am H.C. Wainwright 3rd Annual BioConnect Investor Conference am NASDAQ am 20. Mai 2025 um 11:30 Uhr ET pr盲sentieren. Beide Pr盲sentationen werden per Webcast verf眉gbar sein und f眉r 90 Tage auf der Veranstaltungsseite von Compass archiviert.
- None.
- None.
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May.
Details are as follows:
The Citizens Life Sciences Conference
Location: New York, NY
Date: Thursday, May 8, 2025
Time: 1:30 PM ET
Webcast Link:
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Location: New York, NY
Date: Tuesday, May 20, 2025
Time: 11:30AM ET
Webcast Link:
Virtual/Replay availability:聽Presentations will be archived for 90 days on Compass鈥櫬犔璨共当�.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass鈥檚 scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at聽.
Investor Contact
Media Contact
Anna Gifford, Chief of Staff
617-500-8099
FAQ
What investor conferences will CMPX attend in May 2025?
When is Compass Therapeutics (CMPX) presenting at the Citizens Life Sciences Conference?
How long will CMPX's conference presentations be available for replay?
What type of company is Compass Therapeutics (CMPX)?
